CCND1 and pancreatic neoplasm: Meanwhile, the down-regulated transforming growth factor beta receptor II (TGFBR2) and CCND1 were significantly enriched in both the pathways of chronic myeloid leukemia (p = 9.85E−03) and pancreatic cancer (p = 4.69E−02) (Table 3B).